Navigation Links
ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
Date:1/5/2012

CHARLOTTESVILLE, Va., Jan. 5, 2012 /PRNewswire/ -- ZyGEM Corp. Ltd., a developer and marketer of innovative products for the analysis of DNA and other nucleic acids, and the US Army Medical Research Institute of Infectious Diseases (USAMRIID), today announced the signing of a Cooperative Research and Development Agreement (CRADA) for the development of simplified sample processing solutions for biothreat agents.  The two organizations will collaborate on the development, testing and validation of new solutions for the rapid and efficient extraction of DNA and other nucleic acids for the detection of biothreat agents and other pathogens from a variety of sample matrices, including buffer, serum, whole blood and swabs.

The CRADA effort will leverage ZyGEM's proprietary technology for the extraction of DNA and other nucleic acids from diverse samples using thermophilic enzymes produced by extremophile organisms.  USAMRIID and ZyGEM intend to collaboratively explore the utility of a number of enzymes capable of isolating nucleic acids.  ZyGEM's enzyme technologies will be evaluated and optimized to provide sample processing capabilities for the detection of a variety of biothreat agents and for use in challenging environments. 

ZyGEM currently markets products based on a similar approach.  The unique properties of its EA1 protease, the key ingredient in the company's prepGEM™, forensicGEM™, livestockGEM™ and RNAGEM™ families of nucleic acid extraction kits, make possible cost effective and flexible solutions for researchers performing a wide variety of studies, including human genotyping, animal testing and basic research.  This enzyme has characteristics that make it well-suited for DNA and RNA extraction in a closed tube, where a simple temperature shift modulating enzyme activity rapidly provides high quality DNA and RNA that is ready for analysis by most PCR-based methods, while avoiding the contamination and low yields that can be encountered with other approaches.

"Molecular diagnostics offers the potential to increase the speed, efficiency and accuracy of pathogen detection, but its use has been limited by the fact that isolation of the nucleic acids needed for the analysis is often laborious and inefficient, yielding low quality material that is contingent on the target organism and the sample matrix," noted David Saul, Ph.D., senior scientist at ZyGEM.  "We believe our enzymatic approaches have the potential to enable the rapid preparation of high quality DNA and RNA for the timely detection of biothreat pathogens from a variety of sample matrices simply and efficiently, which could be especially valuable for use in demanding conditions in the field.  We are very pleased to be working with the infectious disease experts at USAMRIID to assess and develop new approaches that seek to harness our unique enzymes to help combat potential biothreats."

About USAMRIIDEstablished in 1969, USAMRIID's mission is to conduct basic and applied research on biological threats resulting in medical solutions – vaccines, drugs and diagnostics – to protect our Nation's armed forces. Its research often has applications that benefit society as a whole.  As the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense, USAMRIID plays a key role in national defense and in infectious disease research.  USAMRIID, located at Fort Detrick, Maryland, is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

About ZyGEMZyGEM Corporation markets nucleic acid extraction solutions based on the company's exclusive collection of microorganisms from extreme environments, with applications in basic research, forensics, clinical diagnostics and agriculture.  ZyGEM's MicroLab unit is developing integrated sample-to-answer systems with the potential to revolutionize DNA testing.  For more information about ZyGEM and its prepGEM™, forensicGEM™, livestockGEM™ and RNAGEM™ nucleic acid extraction kits, visit www.zygem.com.

[The information contained in this press release does not necessarily reflect the position or the policy of the U.S. government and no official endorsement should be inferred.] Contacts:

 Corporate:Media:Paul Kinnon 

GendeLLindheim BioCom PartnersPresident and CEO 

Barbara Lindheim 858 720-8333 

212 584-2276 

blindheim@biocompartners.com


'/>"/>

SOURCE ZyGEM Corp. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Application Note Shows ZyGEMs forensicGEM® Tissue Facilitates Forensic Casework by Rapidly and Reproducibly Extracting DNA From Human Hair
2. ZyGEM Strengthens Senior Management Team With New Appointments
3. Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva
4. ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan
5. ZyGEM Releases Data Confirming its prepGEM(R) Insect Kit is a Simple, Rapid Method for Extracting Insect DNA for Species Identification
6. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
7. ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA
8. ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe
9. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
10. ZyGEM and Advalytix Partner to Produce Innovative DNA Extraction Products
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):